ArticleFrontiers in pain research (Lausanne, Switzerland)2026
Integrated machine learning and multi-omics analysis identifies CYP1B1 as a candidate target of orientin in intervertebral disc degeneration-associated low back pain.
Article in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Orientin is a bioactive agent isolated from natural resources successfully applied for pain control. This study was to explore candidate hub gene of orientin to intervertebral disc degeneration (IDD) -associated low back pain. Methods: This study integrated the network pharmacology analysis using orientin and IDD-associated pain, machine learning and immune infiltration analysis using GSE70362 as prediction analysis. The validation was performed via molecular docking, molecular dynamics simulation, single-cell RNA sequencing (scRNA-seq) analysis and cell experiment using human annulus fibrosus cells under IL-1β stimulation. Results: Network pharmacology analysis showed that there were 368 overlapped genes between orientin and IDD-associated low back pain. Machine learning demonstrated that Cytochrome P450 1B1 (CYP1B1) was candidate hub genes with excellent diagnostic performance (AUC = 0.95). Immune infiltration analysis showed that CYP1B1 had no correlation with infiltration levels of any immune cell subset cells after Benjamini-Hochberg false discovery rate correction. Molecular Docking showed docking energies of orientin to CYP1B1 were all smaller than -9.5 kcal/mol. The molecular dynamics simulation showed a system of orientin-CYP1B1 showed a relatively stable conformational ensemble. scRNA-seq analysis revealed tissue- and cell-type specific expression of CYP1B1, with significant upregulation in annulus fibrosus fibroblasts from diseased samples. In cell experiments, orientin alleviated the decrease in cell viability induced by IL-1β stimulation, and down-regulated CYP1B1 gene expression and CYP1B1 protein levels. Conclusion: This study showed that CYP1B1 is a potential candidate hub gene for orientin to IDD-associated low back pain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.